

Abstract of the Disclosure

5       An aromatic sulfonyl alpha-cycloamino  
hydroxamic acid compound that *inter alia* inhibits  
matrix metalloprotease activity is disclosed as are a  
treatment process that comprises administering a  
contemplated aromatic sulfonyl alpha-cycloamino  
hydroxamic acid compound in a MMP enzyme-inhibiting  
10   effective amount to a host having a condition  
associated with pathological matrix metalloprotease  
activity.